Andrew J. Staples
Director/Miembro de la Junta en Entasis Therapeutics, Inc. .
Cargos activos de Andrew J. Staples
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Director/Miembro de la Junta | 01/05/2015 | - |
Independent Dir/Board Member | 01/05/2015 | - |
Historial de carrera de Andrew J. Staples
Antiguos cargos conocidos de Andrew J. Staples.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ENTASIS THERAPEUTICS HOLDINGS INC. | Director/Miembro de la Junta | 01/05/2015 | 19/06/2019 |
Independent Dir/Board Member | 01/05/2015 | 19/06/2019 |
Formación de Andrew J. Staples.
The University of Sheffield | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Reino Unido | 2 |
Operativa
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Andrew J. Staples
- Experiencia